NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight/Obese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index < 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

Inclusion Criteria:

• Major depressive disorder.
• Antidepressant drug-free.

Exclusion Criteria:

• Schizophrenia
• Mania
• Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
• Obsessive-compulsive disorder
• Post-traumatic stress disorder
• Alcohol or drug abuse/dependence (except for nicotine)
• Active suicidal ideation
• Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement